Robertson KD, Jones PA. Tissue-specific alternative splicing in the human INK4a/ARF cell cycle regulatory locus. Oncogene. 1999;18(26):3810–20.

CAS  Article  Google Scholar 

Goldstein AM, Chan M, Harland M, Hayward NK, Demenais F, Bishop DT, et al. Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet. 2007;44(2):99–106.

CAS  Article  Google Scholar 

Harinck F, Kluijt I, van der Stoep N, Oldenburg RA, Wagner A, Aalfs CM, et al. Indication for CDKN2A-mutation analysis in familial pancreatic cancer families without melanomas. J Med Genet. 2012;49(6):362–5.

CAS  Article  Google Scholar 

Potrony M, Puig-Butillé JA, Aguilera P, Badenas C, Carrera C, Malvehy J, et al. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. J Am Acad Dermatol. 2014;71(5):888–95.

CAS  Article  Google Scholar 

Ranade K, Hussussian CJ, Sikorski RS, Varmus HE, Goldstein AM, Tucker MA, et al. Mutations associated with familial melanoma impair p16INK4 function. Nat Genet. 1995;10(1):114–6.

CAS  Article  Google Scholar 

Baker DJ, Childs BG, Durik M, Wijers ME, Sieben CJ, Zhong J, et al. Naturally occurring p16(Ink4a)-positive cells shorten healthy lifespan. Nature. 2016;530(7589):184–9.

CAS  Article  Google Scholar 

Mountzios G, Rampias T, Psyrri A. The mutational spectrum of squamous-cell carcinoma of the head and neck: targetable genetic events and clinical impact. Ann Oncol. 2014;25(10):1889–900.

CAS  Article  Google Scholar 

Leemans CR, Snijders PJF, Brakenhoff RH. The molecular landscape of head and neck cancer. Nat Rev Cancer. 2018;18(5):269–82.

CAS  Article  Google Scholar 

McLaughlin-Drubin ME, Crum CP, Münger K. Human papillomavirus E7 oncoprotein induces KDM6A and KDM6B histone demethylase expression and causes epigenetic reprogramming. Proc Natl Acad Sci USA. 2011;108(5):2130–5.

CAS  Article  Google Scholar 

Fostira F, Koutsodontis G, Vagia E, Economopoulou P, Kotsantis I, Sasaki C, et al. Predisposing germline mutations in young patients with squamous cell cancer of the oral cavity. JCO Precis Oncol. 2018;2:1–8.

Google Scholar 

Oldenburg RA, de Vos tot Nederveen Cappel WH, van Puijenbroek M, van den Ouweland A, Bakker E, Griffioen G, et al. Extending the p16-Leiden tumour spectrum by respiratory tract tumours. J Med Genet. 2004;41(3):e31.

CAS  Article  Google Scholar 

Schneider-Stock R, Giers A, Motsch C, Boltze C, Evert M, Freigang B, et al. Hereditary p16-Leiden mutation in a patient with multiple head and neck tumors. Am J Hum Genet. 2003;72(1):216–8.

CAS  Article  Google Scholar 

Vinarsky V, Fine RL, Assaad A, Qian Y, Chabot JA, Su GH, et al. Head and neck squamous cell carcinoma in FAMMM syndrome. Head Neck. 2009;31(11):1524–7.

Article  Google Scholar 

Yarbrough WG, Aprelikova O, Pei H, Olshan AF, Liu ET. Familial tumor syndrome associated with a germline nonfunctional p16INK4a allele. J Natl Cancer Inst. 1996;88(20):1489–91.

CAS  Article  Google Scholar 

Yu KK, Zanation AM, Moss JR, Yarbrough WG. Familial head and neck cancer: molecular analysis of a new clinical entity. Laryngoscope. 2002;112(9):1587–93.

CAS  Article  Google Scholar 

Ghiorzo P, Villaggio B, Sementa AR, Hansson J, Platz A, Nicoló G, et al. Expression and localization of mutant p16 proteins in melanocytic lesions from familial melanoma patients. Hum Pathol. 2004;35(1):25–33.

CAS  Article  Google Scholar 

Walker GJ, Gabrielli BG, Castellano M, Hayward NK. Functional reassessment of P16 variants using a transfection-based assay. Int J Cancer. 1999;82(2):305–12.

CAS  Article  Google Scholar 

Goldstein AM, Chan M, Harland M, Gillanders EM, Hayward NK, Avril MF, et al. High-risk melanoma susceptibility genes and pancreatic cancer, neural system tumors, and uveal melanoma across GenoMEL. Cancer Res. 2006;66(20):9818–28.

CAS  Article  Google Scholar 

Vasen H, Ibrahim I, Ponce CG, Slater EP, Matthäi E, Carrato A, et al. Benefit of surveillance for pancreatic cancer in high-risk individuals: outcome of long-term prospective follow-up studies from three european expert centers. J Clin Oncol. 2016;34(17):2010–9.

CAS  Article  Google Scholar 

Soura E, Eliades PJ, Shannon K, Stratigos AJ, Tsao H. Hereditary melanoma: update on syndromes and management: genetics of familial atypical multiple mole melanoma syndrome. J Am Acad Dermatol. 2016;74(3):395–407.

Article  Google Scholar 

Aslanian HR, Lee JH, Canto MI. AGA clinical practice update on pancreas cancer screening in high-risk individuals: expert review. Gastroenterology. 2020;159(1):358–62.

CAS  Article  Google Scholar 

Bahuau M, Vidaud D, Jenkins RB, Bièche I, Kimmel DW, Assouline B, et al. Germ-line deletion involving the INK4 locus in familial proneness to melanoma and nervous system tumors. Cancer Res. 1998;58(11):2298–303.

CAS  PubMed  Google Scholar 

Cabanillas R, Astudillo A, Valle M, de la Rosa J, Álvarez R, Durán NS, et al. Novel germline CDKN2A mutation associated with head and neck squamous cell carcinomas and melanomas. Head Neck. 2013;35(3):E80–4.

Article  Google Scholar 

Della Torre G, Pasini B, Frigerio S, Donghi R, Rovini D, Delia D, et al. CDKN2A and CDK4 mutation analysis in Italian melanoma-prone families: functional characterization of a novel CDKN2A germ line mutation. Br J Cancer. 2001;85(6):836–44.

CAS  Article  Google Scholar 

Sun S, Pollock PM, Liu L, Karimi S, Jothy S, Milner BJ, et al. CDKN2A mutation in a non-FAMMM kindred with cancers at multiple sites results in a functionally abnormal protein. Int J Cancer. 1997;73(4):531–6.

CAS  Article  Google Scholar 

Whelan AJ, Bartsch D, Goodfellow PJ. Brief report: a familial syndrome of pancreatic cancer and melanoma with a mutation in the CDKN2 tumor-suppressor gene. N Engl J Med. 1995;333(15):975–7.

CAS  Article  Google Scholar 

Chan SH, Lim WK, Michalski ST, Lim JQ, Ishak NDB, Met-Domestici M, et al. Germline hemizygous deletion of CDKN2A-CDKN2B locus in a patient presenting with Li-Fraumeni syndrome. NPJ Genom Med. 2016;1:16015.

Article  Google Scholar 

Goldstein AM, Stacey SN, Olafsson JH, Jonsson GF, Helgason A, Sulem P, et al. CDKN2A mutations and melanoma risk in the Icelandic population. J Med Genet. 2008;45(5):284–9.

CAS  Article  Google Scholar 

Borg A, Sandberg T, Nilsson K, Johannsson O, Klinker M, Måsbäck A, et al. High frequency of multiple melanomas and breast and pancreas carcinomas in CDKN2A mutation-positive melanoma families. J Natl Cancer Inst. 2000;92(15):1260–6.

CAS  Article  Google Scholar 

Hewitt C, Lee WuC, Evans G, Howell A, Elles RG, Jordan R, et al. Germline mutation of ARF in a melanoma kindred. Hum Mol Genet. 2002;11(11):1273–9.

CAS  Article  Google Scholar 

Prowse AH, Schultz DC, Guo S, Vanderveer L, Dangel J, Bove B, et al. Identification of a splice acceptor site mutation in p16INK4A/p14ARF within a breast cancer, melanoma, neurofibroma prone kindred. J Med Genet. 2003;40(8):e102.

CAS  Article  Google Scholar 

Monnerat C, Chompret A, Kannengiesser C, Avril MF, Janin N, Spatz A, et al. BRCA1, BRCA2, TP53, and CDKN2A germline mutations in patients with breast cancer and cutaneous melanoma. Fam Cancer. 2007;6(4):453–61.

CAS  Article  Google Scholar 

Shah V, Boyd KD, Houlston RS, Kaiser MF. Constitutional mutation in CDKN2A is associated with long term survivorship in multiple myeloma: a case report. BMC Cancer. 2017;17(1):718.

Article  Google Scholar 

Vanneste R, Smith E, Graham G. Multiple neurofibromas as the presenting feature of familial atypical multiple malignant melanoma (FAMMM) syndrome. Am J Med Genet A. 2013;161a(6):1425–31.

Article  Google Scholar 

Lynch HT, Brand RE, Hogg D, Deters CA, Fusaro RM, Lynch JF, et al. Phenotypic variation in eight extended CDKN2A germline mutation familial atypical multiple mole melanoma-pancreatic carcinoma-prone families: the familial atypical mole melanoma-pancreatic carcinoma syndrome. Cancer. 2002;94(1):84–96.

CAS  Article  Google Scholar 

Fiala EM, Jayakumaran G, Mauguen A, Kennedy JA, Bouvier N, Kemel Y, et al. Prospective pan-cancer germline testing using MSK-IMPACT informs clinical translation in 751 patients with pediatric solid tumors. Nat Cancer. 2021;2:357–65.

Article  Google Scholar 

Jouenne F, ChauvotdeBeauchene I, Bollaert E, Avril MF, Caron O, Ingster O, et al. Germline CDKN2A/P16INK4A mutations contribute to genetic determinism of sarcoma. J Med Genet. 2017;54(9):607–12.

CAS  Article  Google Scholar 

Petronzelli F, Sollima D, Coppola G, Martini-Neri ME, Neri G, Genuardi M. CDKN2A germline splicing mutation affecting both p16(ink4) and p14(arf) RNA processing in a melanoma/neurofibroma kindred. Genes Chromosomes Cancer. 2001;31(4):398–401.

CAS  Article  Google Scholar 

Petty EM, Gibson LH, Fountain JW, Bolognia JL, Yang-Feng TL, Housman DE, et al. Molecular definition of a chromosome 9p21 germ-line deletion in a woman with multiple melanomas and a plexiform neurofibroma: implications for 9p tumor-suppressor gene(s). Am J Hum Genet. 1993;53(1):96–104.

CAS  PubMed  PubMed Central  Google Scholar 

Sargen MR, Merrill SL, Chu EY, Nathanson KL. CDKN2A mutations with p14 loss predisposing to multiple nerve sheath tumours, melanoma, dysplastic naevi and internal malignancies: a case series and review of the literature. Br J Dermatol. 2016;175(4):785–9.

CAS  Article  Google Scholar